Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVES: Exercise and Atorvastatin in Metastatic Cancer
NCT05796973Phase 3Recruiting
- Sponsor
- Tampere University Hospital
- Start
- Mar 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atorvastatin in breast cancer, kidney cancer, ovarian cancer and 1 more (3 arms), sponsored by Tampere University Hospital. Primary endpoints: Time to cancer progression at 24 months and Mortality at 24 months. Started Mar 2023; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
breast cancerkidney cancerovarian cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT05796973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05796973.